China Pharma Holdings, Inc. (CPHI) stock
CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
$0.52−0.04 (-7.47%)
Close on Nov 13, 2026Market cap $22.29MP/E –Yield –
China Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
China Pharma's operating income for the twelve months ending Jun 30, 2026 was -$4.38M. For fiscal 2025 it was -$3.24M. The highest annual figure on record is $24.66M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.24M | – |
| FY2024 | Dec 31, 2024 | -$4.59M | – |
| FY2023 | Dec 31, 2023 | -$2.75M | – |
| FY2022 | Dec 31, 2022 | -$3.55M | – |
| FY2021 | Dec 31, 2021 | -$2.86M | – |
| FY2020 | Dec 31, 2020 | -$2.58M | – |
| FY2019 | Dec 31, 2019 | -$20.41M | – |
| FY2018 | Dec 31, 2018 | -$10.45M | – |
| FY2017 | Dec 31, 2017 | -$18.68M | – |
| FY2016 | Dec 31, 2016 | -$8.16M | – |
| FY2015 | Dec 31, 2015 | -$14.30M | – |
| FY2014 | Dec 31, 2014 | -$38.76M | – |
| FY2013 | Dec 31, 2013 | -$18.61M | -415.1% |
| FY2012 | Dec 31, 2012 | $5.91M | -73.2% |
| FY2011 | Dec 31, 2011 | $22.03M | -10.7% |
| FY2010 | Dec 31, 2010 | $24.66M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$628.15K | – |
| Q2 FY2025 | Jun 30, 2025 | -$652.12K | – |
| Q1 FY2025 | Mar 31, 2025 | -$758.62K | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$916.05K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.18M | – |
| Q3 FY2023 | Sep 30, 2023 | -$713.54K | – |
| Q2 FY2023 | Jun 30, 2023 | -$456.31K | – |
| Q1 FY2023 | Mar 31, 2023 | -$397.48K | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$688.65K | – |
| Q2 FY2022 | Jun 30, 2022 | -$779.59K | – |
| Q1 FY2022 | Mar 31, 2022 | -$911.72K | – |
| Q4 FY2021 | Dec 31, 2021 | -$648.69K | – |
| Q3 FY2021 | Sep 30, 2021 | -$762.40K | – |
| Q2 FY2021 | Jun 30, 2021 | -$752.95K | -1104.1% |
| Q1 FY2021 | Mar 31, 2021 | -$696.47K | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$952.49K | – |
| Q2 FY2020 | Jun 30, 2020 | $74.99K | – |
| Q1 FY2020 | Mar 31, 2020 | -$599.28K | – |
| Q4 FY2019 | Dec 31, 2019 | -$18.68M | – |
| Q3 FY2019 | Sep 30, 2019 | -$645.20K | – |
| Q2 FY2019 | Jun 30, 2019 | -$752.97K | – |
| Q1 FY2019 | Mar 31, 2019 | -$334.21K | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.51M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$864.40K | – |
| Q1 FY2018 | Mar 31, 2018 | -$140.69K | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.69M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.06M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.13M | – |
| Q1 FY2017 | Mar 31, 2017 | -$802.63K | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.06M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.55M | – |
See a number that looks wrong?